Normal Tissue Adjacent to Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Hippo-related Genes in Hepatocellular Carcinoma

Overview

Journal Cancer Med

Specialty Oncology

Date 2021 Apr 5

PMID 33818013

Citations 12

Authors

Qingbo Pan

Fanbo Qin

Hanyu Yuan

Baoning He

Ni Yang

Yitong Zhang

Hong Ren

Yi Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is the most common malignant disease worldwide. Although the diagnosis and treatment of HCC have greatly improved in the recent years, there is still a lack of accurate methods to predict the prognosis of patients. Evidence has shown that Hippo signaling in tissues adjacent to HCC plays a significant role in HCC development. In the present study, we aimed to construct a model based on the expression of Hippo-related genes (HRGs) in tissues adjacent to HCC to predict the prognosis of HCC patients.

Methods: Gene expression data of paired normal tissues adjacent to HCC (PNTAH) and clinical information were obtained from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. The HRG signature was constructed using four canonical Hippo-related pathways. Univariate Cox regression analysis was used to screen survival-related HRGs. LASSO and multivariate Cox regression analyses were used to construct the prognostic model. The true and false positive rates of the model were confirmed using receiver operating characteristic (ROC) analysis.

Results: The prognostic model was constructed based on the expression levels of five HRGs (NF2, MYC, BIRC3, CSNK1E, and MINK1) in PNTAH. The mortality rate of HCC patients increased as the risk score determined by the model increased. Furthermore, the risk score was found to be an independent risk factor for the survival of patients. ROC analysis showed that the prognostic model had a better predictive value than the other conventional clinical parameters. Moreover, the reliability of the prognostic model was confirmed in TCGA-LIHC cohort. A nomogram was generated to predict patient survival. An exploration of the predictive value of the model in HCC tissues indicated that the model is PNTAH-specific.

Conclusions: We developed and validated a prognostic model based on the expression levels of five HRGs in PNTAH, and this model should be helpful in predicting the prognosis of patients with HCC.

Citing Articles

Upregulation of Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases.

Draskovic T, Rankovic B, Zidar N, Hauptman N Genes (Basel). 2025; 15(12.

PMID: 39766812 PMC: 11675665. DOI: 10.3390/genes15121545.

Clinical Potential of Misshapen/NIKs-Related Kinase (MINK) 1-A Many-Sided Element of Cell Physiology and Pathology.

Kot A, Koszewska D, Ochman B, Swietochowska E Curr Issues Mol Biol. 2024; 46(12):13811-13845.

PMID: 39727954 PMC: 11727420. DOI: 10.3390/cimb46120826.

Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.

Xu C, Su R, Lu Z, Song Y, Zhang X, Shu W Genes Genomics. 2024; 46(9):1045-1058.

PMID: 39078588 DOI: 10.1007/s13258-024-01548-0.

Integrated clinical and prognostic analyses of mTOR/Hippo pathway core genes in hepatocellular carcinoma.

Feng T, Chen P, Wang T, Lai C, Yao Y J Physiol Biochem. 2024; 80(2):439-449.

PMID: 38468074 PMC: 11074052. DOI: 10.1007/s13105-024-01015-0.

PGK1 is a potential biomarker for early diagnosis and prognosis of hepatocellular carcinoma.

Yi J, Luo X, Huang W, Yang W, Qi Y, He J Oncol Lett. 2024; 27(3):109.

PMID: 38304170 PMC: 10831403. DOI: 10.3892/ol.2024.14242.

References

Chen Y, Xu Y, Zhao M, Liu Y, Gong M, Xie C . High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. Oncoimmunology. 2016; 5(10):e1219010. PMC: 5087304. DOI: 10.1080/2162402X.2016.1219010. View

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

Palaskas N, Larson S, Schultz N, Komisopoulou E, Wong J, Rohle D . 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011; 71(15):5164-74. PMC: 3148325. DOI: 10.1158/0008-5472.CAN-10-4633. View

Popow O, Paulo J, Tatham M, Volk M, Rojas-Fernandez A, Loyer N . Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin-Independent Targets by Proteomics. Mol Cancer Res. 2019; 17(9):1828-1841. PMC: 7302431. DOI: 10.1158/1541-7786.MCR-18-1154. View

Huang X, Stern D, Zhao H . Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival--Evidence from TCGA Pan-Cancer Data. Sci Rep. 2016; 6:20567. PMC: 4738355. DOI: 10.1038/srep20567. View

Georgescu M, Nanda A, Li Y, Mobley B, Faust P, Raisanen J . Mutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningioma-A Multicenter Study with High Prognostic Relevance. Cancers (Basel). 2020; 12(1). PMC: 7016786. DOI: 10.3390/cancers12010225. View

Wang D, Berglund A, Kenchappa R, Forsyth P, Mule J, Etame A . BIRC3 is a novel driver of therapeutic resistance in Glioblastoma. Sci Rep. 2016; 6:21710. PMC: 4757860. DOI: 10.1038/srep21710. View

Moya I, Castaldo S, Van den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J . Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science. 2019; 366(6468):1029-1034. DOI: 10.1126/science.aaw9886. View

Galandiuk S, Rodriguez-Justo M, Jeffery R, Nicholson A, Cheng Y, Oukrif D . Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology. 2011; 142(4):855-864.e8. PMC: 4446968. DOI: 10.1053/j.gastro.2011.12.004. View

10.

Chen C, Yang H, Iloeje U . Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009; 49(5 Suppl):S72-84. DOI: 10.1002/hep.22884. View

11.

Vibert E, Schwartz M, Olthoff K . Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020; 72(2):262-276. DOI: 10.1016/j.jhep.2019.11.017. View

12.

Harvey K, Zhang X, Thomas D . The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13(4):246-57. DOI: 10.1038/nrc3458. View

13.

Cai J, Song X, Wang W, Watnick T, Pei Y, Qian F . A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev. 2018; 32(11-12):781-793. PMC: 6049514. DOI: 10.1101/gad.315127.118. View

14.

Hong A, Meng Z, Plouffe S, Lin Z, Zhang M, Guan K . Critical roles of phosphoinositides and NF2 in Hippo pathway regulation. Genes Dev. 2020; 34(7-8):511-525. PMC: 7111263. DOI: 10.1101/gad.333435.119. View

15.

Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C . The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2005; 8(1):27-36. DOI: 10.1038/ncb1339. View

16.

Hoglund M . Bladder cancer, a two phased disease?. Semin Cancer Biol. 2006; 17(3):225-32. DOI: 10.1016/j.semcancer.2006.02.002. View

17.

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

18.

Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B . Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015; 17(9):1218-27. PMC: 6186417. DOI: 10.1038/ncb3216. View

19.

Huang Y, Chen S, Qin W, Wang Y, Li L, Li Q . A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma. Front Oncol. 2020; 10:580513. PMC: 7673432. DOI: 10.3389/fonc.2020.580513. View

20.

Cao J, Qiu J, Wang X, Lu Z, Wang D, Feng H . Identification of microRNA-124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF-κB pathway. J Cancer. 2018; 9(17):3006-3015. PMC: 6134807. DOI: 10.7150/jca.25956. View